Learn how you can manage and alleviate your current side effects while actively working to prevent a relapse or secondary cancer using evidence-based, non-toxic therapies.
Click the orange button to the right to learn more.
If you are reading this post because you have been diagnosed with leukoplakia you have come to the right blog post. While leukoplakia is a form of pre-cancer and can lead to oral cancer, the risk of this happening to you is probably pretty low. Your problem is that researchers really don’t know how frequently leukoplakia becomes oral cancer. Two of the articles linked below estimate leukoplakia advancing to oral cancer between 3% and 34%. A wide ranging estimate like that tells me that leukoplakia is not well-understood by conventional oncology. That is not a criticism, it is a statement of fact.
Make no mistake. The size of this diagnosis world-wide is large. The prevalence of oral leukoplakia varies around the world, but generally speaking it is not an uncommon condition. Reported prevalence estimates range from less than 1% to more than 5% in the general population. Leukoplakia is therefore the most common premalignant lesion that occurs in the mouth.
Being a cancer survivor myself, I encourage you to take this diagnosis as a sign to build some evidence-based, anti-cancer, anti-leukoplakia therapies into your life. If you use tobacco, stop. Consider surgically removing the lesion with either a scalpel, a laser or with cryotherapy. According to the article about curcumin linked below, in-human studies have shown that curcumin was safe and effective as a non-toxic therapy.
Keep in mind that curcumin is difficult for the body to absorb in its natural state. Scroll all the way down the page to read about the most bioavailable curcumin formulas.
I have taken curcumin myself for years. If you have any questions scroll down the page, post a question or comment and I will reply to you ASAP.
“Leukoplakia generally refers to a firmly attached white patch on a mucous membrane which is associated with an increased risk of cancer. … It usually occurs within the mouth, although sometimes mucosa in other parts of the gastrointestinal tract, urinary tract, or genitals may be affected.
It is a precancerous lesion, a tissue alteration in which cancer is more likely to develop. The chance of cancer formation depends on the type, with between 3–15% of localized leukoplakia and 70–100% of proliferative leukoplakia developing into squamous cell carcinoma.…”
“Curcumin is a component of turmeric, a spice that is harvested from the rhizomes of the root of a herbaceous perennial plant of the ginger family (Curcuma longa).1 Turmeric has been used for its medicinal properties for thousands of years, and is a commonly used spice in Asian and Indian foods.
Curcumin is purported to have multiple health-promoting effects, such as relieving inflammation, pain, and symptoms of metabolic syndromes. There are also claims that curcumin has anticancer properties…
There are multiple studies that suggest that curcumin has anticancer properties, but the majority of these were conducted in vitro.2,3 These studies suggest that curcumin inhibits cell proliferation and induces cell cycle arrest, apoptosis, and senescence — through various mechanisms, across multiple different types of cancer cell lines…
Curcumin has been evaluated in animal models of different cancer types.3 These studies have generally shown that curcumin has antiproliferative effects…
Some in-human studies of curcumin as an anticancer treatment have been conducted. These studies are primarily early pilot studies and have demonstrated that curcumin is safe and well tolerated, even at high doses…
A trial of 223 patients with leukoplakia randomly assigned patients to receive 3.6 g daily of curcumin or placebo for 6 months.9 Curcumin administration resulted in a significantly higher number of clinical responses compared with placebo (67.5% vs 55.3%, respectively; P = .03). However, there was no difference in histological response or durability of response among those who experienced a complete response. Curcumin was well tolerated and there were no safety concerns related to treatment.
“The aim of this systematic review was to ascertain the malignant transformation rate of oral leukoplakia and the associated risk factors.
METHOD: Published literature was searched through several search engines from 1960 to the end of December 2013. The inclusion criteria included ‘leukoplakia’, ‘pre-cancer’, ‘malignant transformation’, ‘follow-up’ and ‘outcome’. Two reviewers extracted the data independently and also assessed the quality of evidence.
RESULTS:The search strategy resulted in 1032 abstracts or full-text articles, of which 24 met the inclusion criteria. There was much variation in the definitions used by the various authors in their original reports to define oral leukoplakia or in the criteria used to recruit their patients for follow-up. The estimated overall (mean) malignant transformation rate for the total population described in these 24 studies amounts to 3.5% (405/11423), with a wide range between 0.13% and 34.0%.
Based on the evidence presented, the features that stand out as significant determinants contributing to malignant potential of OL include
CONCLUSION: The review indicates that drawing meaningful evidence-based conclusions are difficult from retrospective studies of this nature. However, many of the determinants exposed in the review require further investigation by well-designed prospective studies.
“Based on a review of these studies, it is evident that better bioavailability of formulated curcumin (CU) products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism”
A search of the Pubmed database for the word curcumin yields 601 studies spaning health topics from multiple myeloma and colorectal cancer, to chemotherapies that synergizes with CU, to Alzheimer’s Disease, arthritis and more. Based on years of reading studies and personal accounts, I think it is safe to say that CU supplementation is safe and relatively inexpensive.
I have read about myeloma patients taking daily doses of CU from 400 milligrams to 8 grams (1000 milligrams = 1 gram). By almost any measure, CU is a safe, inexpensive wonder drug.
The only challenge is that CU is famously difficult to absorb in the body. In other words, a person has to mix curcumin with some sort of fat (coconut oil, chocolate, etc.) or take a brand of curcumin capsule that is already formulated to be more “bioavailable” in order to derive the full benefit of CU.
The study linked and exerpted below reviews different formulations of CU. The study itself lists the three most bioavailable formulation/brand of CU and I’ve added an excerpt from a further review from Consumerlab.com that lists four additional bioavailable brands of CU.
“CU is a bright yellow chemical produced by some plants. It is the principal curcuminoid of turmeric (Curcuma longa), a member of the ginger family, Zingiberaceae. It is sold as an herbal supplement, cosmetics ingredient, food flavoring, and food coloring.“
“Are you looking for a way to boost every facet of your health with a single spice? It sounds crazy, but turmeric curcumin with BioPerine may be the magic supplement we’ve been seeking. Turmeric benefits the body and mind in more ways than you can imagine. Similar to bone broth, turmeric impacts almost every facet of life. Over 10,000 peer-reviewed and clinical studies support using turmeric for better health…”
“Curcumin is a widely studied natural compound which has shown tremendous in vitro therapeutic potential. Despite that, the clinical efficacy of the native CU is weak due to its low bioavailability and high metabolism in the gastrointestinal tract. During the last decade, researchers have come up with different formulations with a focus on improving the bioavailability of curcumin. As a result, a significant number of bioavailable curcumin-based formulations were introduced with the varying range of enhanced bioavailability.
The purpose of this review is to collate the published clinical studies of CU products with improved bioavailability over conventional (unformulated) CU. Based on the literature search, 11 curcumin formulations with available human bioavailability and pharmacokinetics data were included in this review. Further, the data on clinical study design, analytical method, pharmacokinetic parameters and other relevant details of each formulation were extracted.
Based on a review of these studies, it is evident that better bioavailability of formulated curcumin products is mostly attributed to improved solubility, stability, and possibly low first-pass metabolism. The review hopes to provide a quick reference guide for anyone looking information on these bioavailable curcumin formulations.
Based on the published reports,
exhibited over 100-fold higher bioavailability relative to reference unformulated CU. Suggested mechanisms accounting for improved bioavailability of the formulations and details on the bioanalysis methods are also discussed.”
According to Consumerlab.com:
“Novasol has the highest bioavailability (185 x compared to unforumulated CU), followed by Curcuwin (136 x), Longvida (100 x), Meriva (48 x), BCM-95 (27 x), Curcumin C3 Complex + Bioperene (20 x), and then Theracumin (16 x).”